茂松 直之 (シゲマツ ナオユキ)

Shigematsu, Naoyuki

写真a

所属(所属キャンパス)

医学部 放射線科学教室(治療) (信濃町)

職名

教授

外部リンク

経歴 【 表示 / 非表示

  • 1983年05月
    -
    1985年03月

    慶應義塾大学病院研修医

  • 1985年04月
    -
    1986年03月

    慶應義塾大学助手(専修医)

  • 1986年04月
    -
    1988年03月

    国立東京第二病院医員

  • 1988年04月
    -
    1990年09月

    慶應義塾大学助手

  • 1990年10月
    -
    1993年03月

    シカゴ大学アルゴンヌ国立研究所訪問研究員

全件表示 >>

学歴 【 表示 / 非表示

  • 1983年03月

    慶應義塾, 医学部

    大学, 卒業

学位 【 表示 / 非表示

  • 医学博士, 慶應義塾, 論文, 1990年11月

免許・資格 【 表示 / 非表示

  • 日本医学放射線学会認定放射線専門医, 1988年06月

  • 第一種放射線取扱主任者, 1989年

  • 核医学専門医, 1996年08月

  • 日本医師会認定産業医, 1998年09月

  • 放射線腫瘍学会認定医, 1999年07月

全件表示 >>

 

研究分野 【 表示 / 非表示

  • 放射線科学

  • 放射線科学 (Radiation Science)

 

著書 【 表示 / 非表示

  • よくわかる卵巣癌のすべて

    伊東久夫、茂松直之, 永井書店, 2007年

    担当範囲: 373-377

  • 放射線治療 グリーンマニュアル

    茂松直之, 金原出版株式会社, 2005年

    担当範囲: 12

  • 放射線治療 グリーンマニュアル

    茂松直之, 金原出版株式会社, 2005年

    担当範囲: 13-20

  • 放射線治療 グリーンマニュアル

    茂松直之, 金原出版株式会社, 2005年

    担当範囲: 81-88

  • 放射線治療 グリーンマニュアル

    曽我茂義、茂松直之、小黒草太, 金原出版株式会社, 2005年

    担当範囲: 315-324

全件表示 >>

論文 【 表示 / 非表示

  • Nationwide Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS): first analysis on survival

    Ito K., Saito S., Yorozu A., Kojima S., Kikuchi T., Higashide S., Aoki M., Koga H., Satoh T., Ohashi T., Nakamura K., Katayama N., Tanaka N., Nakano M., Shigematsu N., Dokiya T., Fukushima M., Takahashi Y., Tsukiyama I., Nasu Y., Harada M., Fukagai T., Yamashita T., Matsubara A., Igawa M., Egawa S., Kakehi Y., Katsuoka Y., Kanetake H., Kubota Y., Kumon H., Yamasaki I., Suzuki K., Deguchi T., Ueno M., Naito S., Namiki M., Baba S., Hayakawa K., Hirao Y., Fujioka T., Horie S., Miki T., Murai M., Yoshida H., Itami J., Inoue T., Imai Y., Kataoka M., Kubo A., Shibuya H., Nishio M., Tanaka H., Tanaka Y., Teramukai S., Harada C., Yamashiro K., Kiba T., Kitagawa S., Uno E., Nishimura T., Kinoshita F., Iida S., Maruo S., Miyakoda K., Daimon T., Kawamoto A., Kaneda H., Yoshidomi M., Nishiyama T., Yagi Y., Namitome R., Toya K., Koike N., Yoshida K., Tabata K., Tsumura H., Kimura M., Ishiyama H., Kotani S., Kondo H., Fujimoto K., Hasegawa M., Tamamoto T., Asakawa I., Nishizawa S., Hashida I., Takezawa Y., Harada K., Tanji S., Sato K., Matsuura T., Ariga H., Ehara S., Nakamura R., Hayashi S., Ohtakara K., Kihara K., Hayashi K., Okamoto K.

    International Journal of Clinical Oncology (International Journal of Clinical Oncology)  23 ( 6 ) 1148 - 1159 2018年12月

    ISSN  13419625

     概要を見る

    © 2018, Japan Society of Clinical Oncology. Background: Investigating oncological outcomes in patients registered in the Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS) in terms of biochemical relapse-free survival (bRFS) by the Phoenix and the newly developed J-POPS definitions, exploration of predictive factors for bRFS, and preliminary verification of pitfalls of prostate-specific antigen (PSA) failure definitions. Methods: Between July 2005 and June 2007, 2316 clinically localized patients underwent permanent seed implantation. The primary endpoint was bRFS. One of the secondary endpoints was overall survival (OS). Results: The median age was 69 and performance status was 0 in 99.1% of participants. The median biologically effective dose (BED) was about 180 Gy 2 . During a median follow-up of 60.0 months, 8.4 and 5.9% had PSA failure by the Phoenix and the J-POPS definitions, respectively. The 5-year bRFSs based on the Phoenix and the J-POPS definitions were 89.1 and 91.6%, respectively. The 5-year OS was 97.3%. According to multivariate analyses, only age affected bRFS based on the Phoenix definition, whereas the risk group and BED independently affected bRFS based on the J-POPS definition. A spontaneous PSA decrease was seen in 91.1% of participants after PSA failure based on the Phoenix definition alone, but in only 22.2% after PSA failure based on the J-POPS definition alone. Conclusion: The world’s largest registration study, J-POPS, consisted of patients with longevity, and a highly quality-controlled BED resulted in excellent bRFS and OS. The high likelihood of PSA bounce by the Phoenix definition should be taken into account, especially in younger patients. Clinical trial information: NCT00534196.

  • A Highly Advanced Gastric Cancer Maintaining a Clinical Complete Response after Chemoradiotherapy Comprising S-1 and Cisplatin

    Yura M., Takahashi T., Fukuda K., Nakamura R., Wada N., Fukada J., Kawakubo H., Takeuchi H., Shigematsu N., Kitagawa Y.

    Case Reports in Gastroenterology (Case Reports in Gastroenterology)  12 ( 3 ) 578 - 585 2018年09月

     概要を見る

    © 2018 The Author(s). Published by S. Karger AG, Basel. We report a patient with highly advanced gastric carcinoma who was treated successfully with chemoradiotherapy (CRT) comprising S-1 and cisplatin. The patient was a 71-year-old male who was diagnosed with advanced gastric carcinoma by esophagogastroduodenoscopy (EGD) by medical examination. EGD demonstrated type 3 advanced gastric carcinoma in the posterior wall of the upper gastric body. An abdominal computed tomography (CT) scan showed that the gastric wall was thickened due to gastric primary tumor, and large lymph nodes (LNs) including the lesser curvature LN, anterosuperior LN along the common hepatic artery and some para-aortic LNs were detected. The patient was diagnosed with stage IV advanced gastric carcinoma according to the Japanese classification of gastric carcinoma (cT4a, cN3, cM1 [para-aortic LN], cStage IV). Preoperative CRT was carried out in an attempt to downstage the disease. Remarkable reduction of the primary tumor and metastatic LNs was observed after initial CRT, and radiological examination determined that a partial response had been achieved. Adverse effects included grade 2 anorexia and grade 3 ALP elevation (919 U/ml). No grade 4 or more severe adverse event was observed. After CRT, although we recommended curative surgery, the patient refused surgical treatment and opted for conservative treatment. Thus, we continued S-1 oral administration for 1 year. Five months after beginning CRT, upper endoscopy showed that the tumor had maintained regression and scar formation, in which no cancer cells were detected by endoscopic biopsy. The patient is doing well and has maintained a clinical complete response for more than 42 months without curative surgery. CRT could be considered as an option for treatment of patients with locally advanced gastric carcinoma diagnosed as unresectable, or for those who refuse surgical treatment.

  • Nationwide Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS)

    Ito Kazuto, Saito Shiro, Yorozu Atsunori, Kojima Shinsuke, Kikuchi Takashi, Higashide Satoshi, Aoki Manabu, Koga Hirofumi, Satoh Takefumi, Ohashi Toshio, Nakamura Katsumasa, Katayama Norihisa, Tanaka Nobumichi, Nakano Masahiro, Shigematsu Naoyuki, Dokiya Takushi, Fukushima Masanori, Takahashi Yutaka, Tsukiyama Iwao, Nasu Yasutomo, Harada Masaoki, Fukagai Takashi, Yamashita Takashi, Matsubara Akio, Igawa Mikio, Egawa Shin, Kakehi Yoshiyuki, Katsuoka Youji, Kanetake Hiroshi, Kubota Yoshinobu, Kumon Hiromi, Yamasaki Ichiro, Suzuki Kazuhiro, Deguchi Takashi, Ueno Munehisa, Naito Seiji, Namiki Mikio, Baba Shiro, Hayakawa Kazushige, Hirao Yoshihiko, Fujioka Tomoaki, Horie Shigeo, Miki Tsuneharu, Murai Masaru, Yoshida Hideki, Itami Jun, Inoue Toshihiko, Imai Yutaka, Kataoka Masaaki, Koike Naoyoshi

    International Journal of Clinical Oncology    1 - 12 2018年06月

    ISSN  1341-9625

     概要を見る

    <p>Background: Investigating oncological outcomes in patients registered in the Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS) in terms of biochemical relapse-free survival (bRFS) by the Phoenix and the newly developed J-POPS definitions, exploration of predictive factors for bRFS, and preliminary verification of pitfalls of prostate-specific antigen (PSA) failure definitions. Methods: Between July 2005 and June 2007, 2316 clinically localized patients underwent permanent seed implantation. The primary endpoint was bRFS. One of the secondary endpoints was overall survival (OS). Results: The median age was 69 and performance status was 0 in 99.1% of participants. The median biologically effective dose (BED) was about 180 Gy2. During a median follow-up of 60.0 months, 8.4 and 5.9% had PSA failure by the Phoenix and the J-POPS definitions, respectively. The 5-year bRFSs based on the Phoenix and the J-POPS definitions were 89.1 and 91.6%, respectively. The 5-year OS was 97.3%. According to multivariate analyses, only age affected bRFS based on the Phoenix definition, whereas the risk group and BED independently affected bRFS based on the J-POPS definition. A spontaneous PSA decrease was seen in 91.1% of participants after PSA failure based on the Phoenix definition alone, but in only 22.2% after PSA failure based on the J-POPS definition alone. Conclusion: The world’s largest registration study, J-POPS, consisted of patients with longevity, and a highly quality-controlled BED resulted in excellent bRFS and OS. The high likelihood of PSA bounce by the Phoenix definition should be taken into account, especially in younger patients. Clinical trial information: NCT00534196.</p>

  • Influence of backscatter radiation on cranial bone fixation devices

    Sakamoto Y., Koike N., Takei H., Ohno M., Shigematsu N., Kishi K.

    Journal of Craniofacial Surgery (Journal of Craniofacial Surgery)  29 ( 4 ) 1094 - 1096 2018年06月

    ISSN  1049-2275

     概要を見る

    © 2018 by Mutaz B. Habal, MD. Postoperative radiation can cause ulcer formation, leading to the denudation of skin over alloplastic materials. The influence of backscatter radiation from fixation devices has not been investigated. The aim of this study is to evaluate backscatter dose variations for different cranial bone fixation devices in an experimental model designed to simulate postoperative radiotherapy. The authors assessed the radiation backscatter doses associated with resorbable (PLLA-PGA) and titanium plates. The samples were irradiated with 6 and 10 MV photon beams from a linear accelerator. Measurements were obtained using an ionization chamber and radiochromic films cut from the same batch. As a result, the backscatter radiation of water and PLLA-PGA proportionally decreased as the depth increased. However, the backscatter radiation of the titanium plate increased just above the plate. This depth lies in the region of the scalp. Each material showed a dose of radioactivity that was higher at 10 MV than that at 6 MV. These devices showed a significant difference, which suggested that these materials amplified the dose compared with water at 6 MV. In conclusion, it is supposed that PLLA-PGA should be used to fix the cranium to decrease the potential for radiation ulcers.

  • Long-term results of concurrent chemoradiotherapy with daily-low-dose continuous infusion of 5-fluorouracil and cisplatin (LDFP) for Stage I-II esophageal carcinoma

    Kumabe A., Fukada J., Kota R., Koike N., Shiraishi Y., Seki S., Yoshida K., Kitagawa Y., Shigematsu N.

    Diseases of the Esophagus (Diseases of the Esophagus)  31 ( 4 )  2018年04月

    ISSN  1120-8694

     概要を見る

    © The Author(s) 2017. Published by Oxford University Press on behalf of International Society for Diseases of the Esophagus. All rights reserved. We investigated long-term treatment outcomes and the feasibility of chemoradiotherapy consisting of daily-low-dose 5-fluorouracil and cisplatin (LDFP) chemotherapy plus radiotherapy for Stage I-II squamous cell esophageal cancer. Treatment records from the 2000 through 2008 period were reviewed retrospectively. Fractionated radiotherapy was performed with a total dose of 60 Gy delivered in 2 Gy per fraction. LDFP chemotherapy, as continuous infusion of 200 mg/m 2 5-fluorouracil combined with one hour infusion of 4 mg/m 2 cisplatin, was administered on the same days as radiotherapy. Survival was calculated by the Kaplan-Meier method. Survival, responses, failure patterns, and toxicities were evaluated. Seventy-six (47 stage I and 29 stage II) patients were analyzed with a median follow-up of 93.6 months. The 8-year overall survival (OS), progression-free survival (PFS) and cause-specific survival (CSS) rates were 63.4%, 49.8%, and 76.7%, respectively. The 8-year OS, PFS, and CSS for stage I and stage II patients were 71.0%/56.1%/82.9% and 45.2%/40.2%/66.6%, respectively. Sixty-eight patients (89.5%) completed the treatment regimen. A complete response (CR) was achieved in 68 patients (89.5%). Twenty-five patients (36.8%) experienced recurrence after CR. The failure patterns were (overlap included): local failure (n = 12), nodal metastasis (n = 12), distant metastasis (n = 3), details unknown (n = 2). Salvage therapy was performed for local failure; endoscopic therapy (n = 7) or surgery (n = 2). Six patients remain alive without relapse after salvage endoscopic therapy. Major Grade 3 or higher acute adverse events were leukopenia (22%), anorexia (17%), and esophagitis (11%). Major late toxicities (Grade 3 or 4) involved pericardial effusion (12%), pleural effusion (4%), and esophageal stenosis (3%). Chemoradiotherapy with LDFP provided favorable long-term survival with acceptable toxicity for Stage I-II squamous cell esophageal cancer. The tumor response was excellent, but close endoscopic follow-up is essential for detecting and treating local recurrence.

全件表示 >>

KOARA(リポジトリ)収録論文等 【 表示 / 非表示

研究発表 【 表示 / 非表示

  • Stereotactic body radiotherapy (SBRT) for primary lung cancer at a dose of 50Gy per 5 fractions to the periphery of the planning target volume (PTV) calculated by a superposition algorithm.

    Takeda A, Sanuki N, Kunieda E, Ohashi T, Oku Y, Takeda T, Shigematsu N, Kubo A

    The 50th Annual Meeting of the American Society for Therapeutic Radiology and Oncology (Boston) , 2008年09月, ポスター(一般)

  • Pleural and pericardial effusion after radiotherapy or concurrent chemo-radiotherapy (CCR) for esophageal cancer – single institutional retrospective study.

    Fukada J, Shigematsu N, Kitagawa Y, Ohashi T, Kutsuki S, Kunieda E, Shiraishi Y, Kubo A, Kawase T

    The 50th Annual Meeting of the American Society for Therapeutic Radiology and Oncology (Boston) , 2008年09月, ポスター(一般)

  • Dose distribution analysis of axillary lymph nodes for three-dimensional conformal radiotherapy with a field-in-field technique for breast cancer.

    Ohashi T, Takeda A, Shigematsu N, Fukada J, Sanuki N, Amemiya A, Kubo A

    The 50th Annual Meeting of the American Society for Therapeutic Radiology and Oncology (Boston) , 2008年09月, ポスター(一般)

  • T1-3, N2-3の4期中咽頭癌に対するドセタキセル併用放射線療法±計画的頸部郭清術

    冨田俊樹、今西順久、小澤宏之、坂本耕二、藤井良一、重富征爾、小川郁、茂松直之、深田淳一、藤井正人

    第32回日本頭頚部癌学会 (東京) , 2008年06月, 口頭(一般)

  • 当院における上咽頭癌症例の検討

    藤井良一、冨田俊樹、今西順久、坂本耕二、重富征爾、小川郁、茂松直之、藤井正人

    第32回日本頭頚部癌学会 (東京) , 2008年06月, 口頭(一般)

全件表示 >>

競争的資金等の研究課題 【 表示 / 非表示

  • クロロキンのドラッグリポジショニングによる新規放射線増感治療の開発

    2018年04月
    -
    2021年03月

    文部科学省・日本学術振興会, 科学研究費助成事業, 茂松 直之, 基盤研究(C), 補助金,  代表

  • 腫瘍特異性の高い放射線増感剤の開発-メトフォルミンを用いた胃癌細胞での検討-

    2015年04月
    -
    2018年03月

    文部科学省・日本学術振興会, 科学研究費助成事業, 茂松 直之, 基盤研究(C), 補助金,  代表

受賞 【 表示 / 非表示

  • 日本医学放射線学会電子ポスター(CyPos)賞(Bronze Medal)

    白石悠、深田淳一、茂松直之、北川雄光、大橋俊夫、沓木章二、久保敦司, 2008年04月, 食道癌に対する化学放射線 / 放射線治療後の胸水、心嚢液貯留

    受賞区分: 国内学会・会議・シンポジウム等の賞

  • 日本放射線腫瘍学会ポスター発表学会賞(金賞)

    金田和也、宮澤雷太、深田淳一、茂松直之、大橋俊夫、菅原章友、国枝悦夫、奥洋平、中島淳、久保敦司, 2007年12月, 前立腺シード小線源治療におけるTRUS-CT融合画像を用いた恥骨弓干渉の予測

    受賞区分: 国内学会・会議・シンポジウム等の賞

  • 日本放射線腫瘍学会優秀発表賞

    藤井健太郎、深田淳一、茂松直之、菅原章友、国枝悦夫、中島淳、谷本伸弘、新本弘、伊東良晃、久保敦司, 2006年11月, 前立腺シード小線源治療におけるMIRを用いた恥骨弓競合の予測

    受賞区分: 国内学会・会議・シンポジウム等の賞

  • 日本医学放射線学会優秀論文賞

    茂松 直之, 2005年, Relation between chromosomal aberration and radiation dose during the process of TBI

    受賞区分: 国内学会・会議・シンポジウム等の賞

  • 第1回御園生賞

    戸矢和仁,茂松直之,伊東久夫,山下昌次,久保敦司,金井達明, 1997年03月, X線および重粒子線照射による培養細胞における遺伝子突然変異発生頻度の定量

    受賞区分: 国内学会・会議・シンポジウム等の賞

 

担当授業科目 【 表示 / 非表示

  • 放射線腫瘍学特論

    2019年度

  • 放射線治療学特論

    2019年度

  • 放射線医学特論

    2019年度

  • 症例検討

    2019年度

  • 臨床放射線腫瘍学

    2019年度

全件表示 >>

 

社会活動 【 表示 / 非表示

  • 慶応義塾大学医学部三四会競走部

     
  • Japanese Journal of Clinical Oncology

     
  • 日本放射線腫瘍学研究機構

     
  • 神奈川県保険医協会

     

所属学協会 【 表示 / 非表示

  • 日本医学放射線学会

     
  • 日本核医学会

     
  • 日本癌治療学会

     
  • 日本放射線腫瘍学会

     
  • 日本頭頸部癌学会

     

全件表示 >>

委員歴 【 表示 / 非表示

  •  

    代議員 広報委員, 日本医学放射線学会

  •  

    会員, 日本核医学会

  •  

    会員, 日本癌治療学会

  •  

    評議員 広報委員会副委員長, 日本放射線腫瘍学会

  •  

    会員, 日本頭頸部癌学会

全件表示 >>